Brand Name:Uptravi Drug Class:PAH, Prostacyclin Agonists What is selexipag, and what is it used for? Selexipag is a medication used to treat pulmonary arterialhypertension(PAH), a condition ofhigh blood pressurein the arteries that carry oxygen-depleted blood from theheartto thelungs. Selexipag b...
注册 论文 > 医学论文 > Selexipag 下载文档 收藏 打印 转格式 956阅读文档大小:251.54K3页raul0310上传于2014-11-13格式:PDF selexipag-Thomson Reuters cortellis-2016-02 热度: Selexipag for the treatment of children with pulmonary arterial hypertension first multicenter experience in drug safety and efficacy...
It has subsequently been approved in Canada for the long-term treatment of PAH, and received a positive opinion in the EU for the treatment of PAH in adult patients with WHO functional class II-III. Selexipag received orphan drug designation for the treatment of PAH in Japan in 2014 and is...
7 7.1 DRUG INTERACTIONS Strong CYP2C8 Inhibitors Concomitant administration with strong inhibitors of CYP2C8 may result in a significant increase in exposure to selexipag and its active metabolite. Avoid concomitant administration of UPTRAVI with strong inhibitors of CYP2C8 (e.g., gemfibrozil) [...
Selexipag "offers an additional treatment option" for patients with PAH," Ellis Unger, MD, from the FDA's Center for Drug Evaluation and Research, said in astatement. Actelion Chief Executive Officer Jean-Paul Clozel said selexipag will "significantly expand the options to delay disease progression...
本文对其作用机制、药动学、药效学、临床试验、用法与用量、药物相互作用、安全性以及特殊人群用药等方面做一综述.%Selexipag belongs to a class of drugs called oral selective prostacyclin receptor agonists.The drug acts by relaxing muscles in the walls of blood vessels to dilate blood vessels and ...
mcg twice daily. (2.1) DRUG INTERACTIONS Increase the dose by 200 mcg twice daily at weekly intervals to the highest tolerated dose up to 1600 mcg twice daily. (2.1) Strong CYP2C8 inhibito 内容提供方:yan698698 审核时间:2017-05-27...
The FDA approval of the New Drug Application (NDA) for UPTRAVI®is based upon the findings from a prospective, multi-center, open-label single sequence cross-over Phase 3 study designed to assess the safety, tolerability and pharmacokinetics of temporarily switching be...
As such, the risk assessment is currently recommended for patients with “classical PAH” (i.e., idiopathic/heritable/drug-induced) [27] and requires further validation for the PAH-CHD population, accounting for specifically the unique features of Eisenmenger syndrome patients. Although we observed ...
Uptravi belongs toa class of drugs called oral IP prostacyclin receptor agonists. Thedrug acts by relaxing muscles in the walls of blood vessels to dilate (open)blood vessels and decrease the elevated pressure in the vessels supplying bloodto the lungs. ...